Table 1a.
Demographics and baseline characteristics by chlorhexidine gluconate usage
| High (>75%) N=25 |
Medium (50-75%) N=33 |
Low (<50%) N=45 |
None (0%) N=89 |
P-value1 | |
|---|---|---|---|---|---|
| Median Age (IQR) | 56 (47 - 59) | 58 (52 - 63) | 58 (48 - 62) | 54 (45 - 62) | 0.26 |
| Gender, Female | 11 (44%) | 13 (39.4%) | 19 (42.2%) | 34 (38.2%) | 0.94 |
| Race | 0.41 | ||||
| White | 17 (68%) | 18 (54.5%) | 30 (66.7%) | 65 (73%) | · |
| Black | 7 (28%) | 13 (39.4%) | 12 (26.7%) | 23 (25.8%) | · |
| Other | 1 (4%) | 2 (6.1%) | 3 (6.7%) | 1 (1.1%) | · |
| Hispanic | 0 (0%) | 1 (3%) | 2 (4.4%) | 1 (1.1%) | 0.45 |
| Disease | 0.42 | ||||
| Leukemia | 6 (24%) | 10 (30.3%) | 16 (35.6%) | 29 (32.6%) | · |
| Lymphoma | 8 (32%) | 17 (51.5%) | 16 (35.6%) | 43 (48.3%) | · |
| MDS2 | 7 (28%) | 4 (12.1%) | 8 (17.8%) | 12 (13.5%) | · |
| Other | 4 (16%) | 2 (6.1%) | 5 (11.1%) | 5 (5.6%) | · |
| Disease Status | 0.79 | ||||
| First Complete Remission | 7 (28%) | 12 (36.4%) | 16 (35.6%) | 33 (37.1%) | · |
| Second or Greater CR3 | 1 (4%) | 5 (15.2%) | 5 (11.1%) | 9 (10.1%) | · |
| Partial Remission | 5 (20%) | 7 (21.2%) | 7 (15.6%) | 23 (25.8%) | · |
| Stable | 8 (32%) | 6 (18.2%) | 11 (24.4%) | 13 (14.6%) | · |
| Other | 4 (16%) | 3 (9.1%) | 6 (13.3%) | 11 (12.4%) | · |
| Days from Diagnosis to Transplant (IQR) | 237 (166 - 835) | 288 (170 - 652) | 325.5 (152.5 - 1302.5) | 252 (170 - 764) | 0.20 |
| Days from CR1 to Transplant (IQR) | 35 (7 - 78) | 20 (17 - 23) | 23 (17 - 36) | 17 (12 - 27) | |
| Transplant Type | 0.75 | ||||
| Allogeneic | 15 (60%) | 18 (54.5%) | 30 (66.7%) | 55 (61.8%) | · |
| Karnofsky Performance Status | 0.17 | ||||
| 80 or below | 13 (52%) | 11 (33.3%) | 26 (57.8%) | 40 (44.9%) | · |
| 90-100 | 12 (48%) | 22 (66.7%) | 19 (42.2%) | 49 (55.1%) | · |
| ICU Transfer | 2 (8%) | 3 (9.1%) | 4 (8.9%) | 9 (10.1%) | 0.99 |
| Hospitalization Days (IQR) | 23 (17 - 27) | 22 (17 - 30) | 25 (19 - 31) | 25 (19 - 32) | 0.54 |
| WBCs on Admission4 (IQR) | 4.9 (3.3 - 6.2) | 3.8 (3.1 - 5) | 4.2 (2.1 - 5.7) | 4.9 (3.7 - 6.7) | 0.33 |
| ALC on Admission5 (IQR) | 2250 (1250 - 2318) | 3246 (3246 - 3246) | 1039 (428 - 1634) | 799 (700.5 - 1374) | 0.24 |
| Antibiotic Prophylaxis | 0.0003 | ||||
| Ciprofloxacin | 13 (52%) | 20 (60.6%) | 32 (71.1%) | 68 (76.4%) | · |
| Levofloxacin | 12 (48%) | 10 (30.3%) | 9 (20%) | 7 (7.9%) | · |
| Other6 | 0 (0%) | 3 (9.1%) | 4 (8.9%) | 14 (15.7%) | · |
| Any Infection 30 Days Prior to Transplant | 3 (12%) | 1 (3%) | 3 (6.7%) | 8 (9%) | 0.59 |
1
P-values obtained via ANOVA or chi-square test.
2
MDS: Myelodysplastic Syndrome.
3
CR: Complete Remission.
4
WBC: White blood cell.
5
ALC: Absolute lymphocyte count.
6
Other: Non-fluoroquinolone antibiotic prophylaxis.